Start-up Australia invests in bone-building tech
Monday, 04 April, 2005
Venture capital fund Start-up Australia Ventures has invested AUD$3 million in junior biotech Caldeon, which is collaborating with the University of Western Australia to optimise osteoporosis drug leads which could reduce bone loss.
"This discovery is a genuine first in the bone metabolism field. This is the first agent to be discovered that specifically stimulates and protects the specialised cells responsible for forming bone," said Prof Ming-Hao Zheng, a co-discoverer of the compounds, along with Dr Jiake Xu and Dr Tony Phan.
Start-up Australia has $55 million under management. Its previous investmest include Alchemia, EvoGenix, Mimetica, Promics, Protagonist, Cortical, Iliad Chemicals and Replikun Biotech
The funding is to be supplied in milestone-based tranches.
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
